Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $611.6 million.

  • Relay Therapeutics' Change in Acquisitions & Divestments fell 29.74% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.8 million, marking a year-over-year decrease of 50.18%. This contributed to the annual value of $611.6 million for FY2024, which is 5.52% down from last year.
  • As of FY2024, Relay Therapeutics' Change in Acquisitions & Divestments stood at $611.6 million, which was down 5.52% from $647.3 million recorded in FY2023.
  • Relay Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $647.3 million for FY2023, and its period low was $350.1 million during FY2020.
  • Over the past 3 years, Relay Therapeutics' median Change in Acquisitions & Divestments value was $611.6 million (recorded in 2024), while the average stood at $538.2 million.
  • Per our database at Business Quant, Relay Therapeutics' Change in Acquisitions & Divestments plummeted by 32.87% in 2022 and then surged by 81.96% in 2023.
  • Yearly analysis of 5 years shows Relay Therapeutics' Change in Acquisitions & Divestments stood at $350.1 million in 2020, then spiked by 51.38% to $529.9 million in 2021, then plummeted by 32.87% to $355.7 million in 2022, then skyrocketed by 81.96% to $647.3 million in 2023, then dropped by 5.52% to $611.6 million in 2024.